Welcome to our dedicated page for Relmada Therapeutics news (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics stock.
Relmada Therapeutics Inc (RLMD) is a clinical-stage biotechnology company pioneering novel treatments for central nervous system disorders. This news hub provides investors and researchers with essential updates on the company's progress in developing NMDA receptor antagonists and innovative CNS therapies.
Access timely announcements about clinical trial milestones, regulatory developments, and strategic partnerships. Our curated collection features official press releases and verified news coverage related to RLMD's work in major depressive disorder treatment, chronic pain management, and metabolic disease research.
Key updates include progress reports on late-stage clinical programs, analyses of therapeutic candidates, and corporate developments impacting RLMD's research pipeline. Bookmark this page for direct access to primary source materials and expert commentary on the company's scientific advancements.
Relmada Therapeutics (Nasdaq: RLMD) reported its preliminary financial results for Q4 and full-year 2022, highlighting a net loss of $37.9 million, or $1.28 per diluted share, up from a loss of $34.4 million, or $1.80 per diluted share, a year prior. Full-year losses increased to $157 million from $125.8 million in 2021. The company is focused on advancing REL-1017 for major depressive disorder, making changes to the ongoing Study 302 and initiating Study 304. Cash, cash equivalents, and short-term investments totaled approximately $148.3 million as of December 31, 2022. A conference call is scheduled for March 23, 2023.
Relmada Therapeutics (Nasdaq: RLMD), a late-stage biotechnology firm specializing in CNS diseases, will announce its financial results for Q4 and full-year 2022 post-market on March 23, 2023. This will be followed by a corporate update conference call and webcast at 4:30 PM ET the same day. The company is advancing its lead program, REL-1017, targeting major depressive disorder as an adjunctive treatment. Forward-looking statements highlight potential risks, such as failure in clinical trial efficacy, regulatory approval challenges, and other uncertainties impacting future performance.
FAQ
What is the current stock price of Relmada Therapeutics (RLMD)?
What is the market cap of Relmada Therapeutics (RLMD)?
